The following is a summary of “Role of tumor phenotype in the surgical treatment of early-stage breast cancer,” published in the JANUARY 2023 issue of Surgery by Rooney, et al.
For a study, researchers sought to determine whether tumor phenotype affected surgical choices and how that would affect overall survival (OS) for breast cancer in its early stages.
The National Cancer Database (2010-2017) includes women aged 18 to 69 with breast cancer that was cT0-2/cN0/cM0. The variables connected to the kind of operation were found using a generalized logistic model. In addition, a Kaplan-Meier curve showed unadjusted OS, and OS variations between surgical procedures were investigated using the log-rank test.
About 58% of the 597,149 patients had a lumpectomy with radiation (BCT), 25% had a unilateral mastectomy (UM), and 17% had a bilateral mastectomy (BM). After correction, hormone receptor-positive tumors were more likely to undergo UM than triple-negative (TN) and HER2+ tumors (OR = 0.881, 95% CI = 0.860-0.903; OR = 0.485, 95% CI = 0.470-0.501). BCT had better 5-year OS than UM and BM (UM: 0.926, vs. BM: 0.952, vs. BCT: 0.960).
BCT was being utilized more often to treat HER2+ and TN cancers. However, no matter the tumor phenotype, more involved surgery did not result in greater survival rates.
Reference: americanjournalofsurgery.com/article/S0002-9610(22)00576-1/fulltext
